ClinicalTrials.gg
RecruitingNCT04798820SINGUpdated Jul 15, 2024

The Effect of Intensive Dietary Education on Nutritional Status After Gastrectomy(SING)

An interventional study of Dietary education(nutritional counselling) in Gastric Cancer and Gastrectomy, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Stomach Neoplasms by Samsung Medical Center — 6 open to participants now, 7 under way, none of them phase 3. Stomach Neoplasms · Samsung Medical Center.

Planned enrollment
4th of 32
358 · median 66
Started
2021
with 2 others
No phase
6 of 40
3 open now
Registered
33rd of 40
by date

Among the 40 studies in Stomach Neoplasms by Samsung Medical Center, this one is the 4th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2021, is one of 6 with no phase, and was the 33rd registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 40 studies in Stomach Neoplasms by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Stomach Neoplasms by Samsung Medical Center, or all of them as a file.
02

Study summary

Radical gastrectomy has been known as the most effective treatment of curable gastric cancer.However, there is a high risk of malnutrition and weight loss after a gastrectomy which may be attributed to inadequate oral consumption, malabsorption and loss of the reservoir function of the stomach.Weight loss has been regarded as an independent risk factor for postoperative mortality and morbidity and It is also closely associated with a quality of life after surgery. No specific surgical technique has been proved to be effective in reducing postoperative weight loss and it seems like that dietary education and consultation is the best way to minimize weight loss in gastrectomy patients in clinical setting. In this regard, the investigators performed a retrospective pilot study to identify the effect of routinely performed (simplified) dietary education on nutritional status after gastrectomy, but it revealed that the effect of simplified dietary education on weight loss was not clear and the result implies that more intensive dietary education may be necessary after gastrectomy. The aim of this randomized controlled trial (RCT) is to elucidate the effect of intensive dietary education on nutritional status after gastrectomy in comparison with simplified dietary education.

Read the detailed description

Subject 1: subtotal gastrectomy group

subject 2: total gastrectomy group

Objectives:

Primary objective: to evaluate Weight loss difference of simplified dietary education(SE) versus intensive dietary education(IE) for patients after undergoing a gastrectomy

Primary endpoint: Superiority of weight loss difference (%) of IE group between post op 1mo and 12mo

Secondary objectives:

weight loss(%) of each subgroup, nutritional parameters (PG-SGA), Calrorie intake \& dietary habits, albumin, hemoglobin, iron panel (TIBC, ferritin), Absolute lymphocyte count(ALC), vit B12, homocysteine, quality of life(QOL) change

  1. Nutritional parameters (PG-SGA)
  2. the amount of calorie intake (Kcal, protein) \& dietary habits
  3. Albumin (g/dL)
  4. Hemoglobin (g/dL)
  5. Iron panel [TIBC (μg/dL), Ferritin (ng/mL)]
  6. Absolute lymphocyte count (ALC) (10\^3/μL)
  7. Vitamin B12 (pg/mL)
  8. Homocysteine (μmol/L)
  9. Quality of life of the patients in terms of European quality of life questionnaire (EQ-5D)
03

Conditions studied

  • Gastric Cancer
  • Gastrectomy

Browse trials for

Keywords

  • gastric cancer
  • gastrectomy
  • dietary education
  • nutritional status
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven primary gastric adenocarcinoma,
  • T1N0, T1N1, T2N0, which are assessed by computed tomography (CT) scan (AJCC 8th classification) and intraoperative surgical staging
  • location of primary tumor; antrum, or angle, , lower body or mid body of the stomach
  • No evidence of other distant ,
  • age ≥ 20 year old, ≤ 75 year old
  • no prior or posterior treatment of chemotherapy or radiation therapy against any other
  • adequate organ functions defined as indicated below:

    1. WBC count: 3000/mm3 \~12,000/mm3,
    2. > serum 8.0 g/dL
    3. > serum 100 000/mm3,
    4. \< serum 100 IU/L,
    5. \<serum ALT 100 IU/L,
    6. \< Total 2.0 mg/dL,
  • written signed

Exclusion criteria

Exclusion Criteria:

  • active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer),
  • gastric remnant cancer
  • ≥T3, T4 in surgical staging before resection
  • N2 or more (number of lymph nodes ≥3) in CT scan
  • histologically rare variants in World Health Organization (WHO) Classification such as Adenosquamous, Hepatoid, Squamous cell, Undifferentiated, neuroendocrine carcinoma and others
  • pregnant or breast-feeding women,
  • mental disorder(diagnosed with mental disorder on medical record),
  • unstable angina or myocardial infarction within 6 months of the trial,
  • unstable hypertension,
  • diabetes mellitus on insulin,
  • severe respiratory disease requiring continuous oxygen therapy,
  • previous upper abdominal surgery except laparoscopic cholecystectomy,
  • surgical complication
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
358 participants (estimated)

Study arms

  • Active comparator
    SE-STG

    simplified dietary education arm in subtotal gastrectomy group.

    Other: Dietary education(nutritional counselling)

  • Active comparator
    IE-STG

    intensive dietary education arm in subtotal gastrectomy group

    Other: Dietary education(nutritional counselling)

  • Active comparator
    SE-TG

    simplified dietary education arm in total gastrectomy group.

    Other: Dietary education(nutritional counselling)

  • Active comparator
    IE-TG

    intensive dietary education arm in total gastrectomy group

    Other: Dietary education(nutritional counselling)

Interventions

  • OtherDietary education(nutritional counselling)

    Dietary education provided to gastrectomy patients by dietitian.

06

What researchers measure

Primary outcomes

  1. Change from preoperative weight change at immediate postoperative period in SE and IE groups.

    comparison of weight change between the two groups after surgery

    Time frame: preoperative, immediate postoperative

  2. Change from preoperative weight change at postoperaive 1 month in SE and IE groups.

    comparison of weight change between the two groups after surgery

    Time frame: preoperative, postoperative 1 month

  3. Change from preoperative weight change at postoperaive 3 months in SE and IE groups.

    comparison of weight change between the two groups after surgery

    Time frame: preoperative, postoperative 3 months

  4. Change from preoperative weight change at postoperaive 6 months in SE and IE groups.

    comparison of weight change between the two groups after surgery

    Time frame: preoperative, postoperative 6 months

  5. Change from preoperative weight change at postoperaive 12 months in SE and IE groups.

    comparison of weight change between the two groups after surgery

    Time frame: preoperative, postoperative 12 months

  6. Change from preoperative weight change at postoperaive 18 months in SE and IE groups.

    comparison of weight change between the two groups after surgery

    Time frame: preoperative, postoperative 18 months

Secondary outcomes

  1. Nutritional parameters

    measured by Patient-Generated Subjective Global Assessment (PG-SGA; rating A,B,C)

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  2. 24hrs dietary recall

    calculating kcal \& protein intake by 24hrs dietary recall (questionnaire)

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  3. dietary habits

    number of meals, eating speed (questionnaire)

    Time frame: preoperative, immediate postoperative, postoperative 1 months, 3 months, 6months, 12 months, 18 months

  4. Albumin

    g/dL

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  5. Hemoglobin

    g/dL

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  6. Total iron binding capacity (TIBC)

    μg/dL

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  7. Ferritin

    ng/mL

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  8. Absolute lymphocyte count (ALC)

    10\^3/μL

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  9. Vitamin B12

    pg/mL

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  10. Homocysteine

    μmol/L

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

  11. Quality of life of the patients

    European quality of life questionnaire (EQ-5D); the descriptive system which comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems (labelled 1-3).

    Time frame: preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Oct 2024, 43 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 43 months is above that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 15, 2021
StartActual
Mar 9, 2021
Primary completionEst.
Oct 2024
CompletionEst.
Oct 2025
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04798820
Responsible party
Jae Moon Bae (Professor, Samsung Medical Center) — Principal investigator
First posted
Mar 15, 2021
Start date
Mar 9, 2021
Primary completion
Oct 2024 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jul 15, 2024

Study contacts

Jae-Moon Bae, MD, Ph.D
Contact
jmoon.bae@samsung.com
82-2-3410-0252
Aron Lee, RD
Contact
82-2-3410-0498
Aron Lee, RD
study director · Samsung Medical Center
Bo Ram Park, Ph.D.
study director · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion